Neuberger Berman Group LLC trimmed its stake in Humana Inc. (NYSE:HUM – Get Rating) by 31.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 205,469 shares of the insurance provider’s stock after selling 95,620 shares during the period. Neuberger Berman Group LLC owned 0.16% of Humana worth $89,415,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Riverview Trust Co purchased a new stake in shares of Humana in the 1st quarter worth $32,000. Transcend Capital Advisors LLC boosted its holdings in Humana by 18.3% in the 1st quarter. Transcend Capital Advisors LLC now owns 587 shares of the insurance provider’s stock worth $255,000 after buying an additional 91 shares during the period. Krane Funds Advisors LLC boosted its holdings in Humana by 4.2% in the 1st quarter. Krane Funds Advisors LLC now owns 889 shares of the insurance provider’s stock worth $387,000 after buying an additional 36 shares during the period. CCLA Investment Management Ltd boosted its holdings in Humana by 1.4% in the 1st quarter. CCLA Investment Management Ltd now owns 218,232 shares of the insurance provider’s stock worth $95,075,000 after buying an additional 3,034 shares during the period. Finally, Meeder Asset Management Inc. bought a new position in Humana in the 1st quarter worth $800,000. 93.50% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
HUM has been the subject of several recent analyst reports. Sanford C. Bernstein initiated coverage on shares of Humana in a report on Thursday, May 26th. They issued a “market perform” rating and a $506.00 target price for the company. Loop Capital initiated coverage on shares of Humana in a report on Thursday, June 16th. They issued a “buy” rating and a $510.00 target price for the company. Deutsche Bank Aktiengesellschaft upped their target price on shares of Humana from $450.00 to $514.00 in a report on Thursday, July 28th. SVB Leerink increased their price objective on shares of Humana from $535.00 to $540.00 and gave the company an “outperform” rating in a report on Thursday, July 28th. Finally, Credit Suisse Group set a $548.00 price objective on shares of Humana in a report on Tuesday, July 19th. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $515.17.
Humana Stock Performance
Humana (NYSE:HUM – Get Rating) last posted its quarterly earnings data on Wednesday, July 27th. The insurance provider reported $8.67 earnings per share for the quarter, topping analysts’ consensus estimates of $7.67 by $1.00. Humana had a net margin of 3.52% and a return on equity of 18.42%. The company had revenue of $23.66 billion for the quarter, compared to analyst estimates of $23.44 billion. During the same period in the prior year, the company posted $6.89 EPS. The firm’s revenue for the quarter was up 14.6% on a year-over-year basis. Research analysts forecast that Humana Inc. will post 25 EPS for the current year.
Humana Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 30th will be given a $0.7875 dividend. This represents a $3.15 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend is Thursday, September 29th. Humana’s dividend payout ratio (DPR) is currently 12.86%.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.